Perseus Proteomics Inc
TSE:4882

Watchlist Manager
Perseus Proteomics Inc Logo
Perseus Proteomics Inc
TSE:4882
Watchlist
Price: 570 JPY -3.72% Market Closed
Market Cap: 8.4B JPY
Have any thoughts about
Perseus Proteomics Inc?
Write Note

Perseus Proteomics Inc
Cash Taxes Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Perseus Proteomics Inc
Cash Taxes Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Taxes Paid CAGR 3Y CAGR 5Y CAGR 10Y
Perseus Proteomics Inc
TSE:4882
Cash Taxes Paid
ÂĄ1.9m
CAGR 3-Years
1%
CAGR 5-Years
15%
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
Cash Taxes Paid
ÂĄ2.4B
CAGR 3-Years
53%
CAGR 5-Years
60%
CAGR 10-Years
49%
PeptiDream Inc
TSE:4587
Cash Taxes Paid
ÂĄ2.2B
CAGR 3-Years
-3%
CAGR 5-Years
15%
CAGR 10-Years
44%
Takara Bio Inc
TSE:4974
Cash Taxes Paid
ÂĄ914m
CAGR 3-Years
-43%
CAGR 5-Years
-7%
CAGR 10-Years
0%
Pharma Foods International Co Ltd
TSE:2929
Cash Taxes Paid
ÂĄ685m
CAGR 3-Years
45%
CAGR 5-Years
49%
CAGR 10-Years
67%
C
Cuorips Inc
TSE:4894
Cash Taxes Paid
ÂĄ2.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Perseus Proteomics Inc
Glance View

Market Cap
8.4B JPY
Industry
Biotechnology

Perseus Proteomics, Inc. is a holding company that develops antibody-based therapeutics and diagnostics. The company is headquartered in Meguro-Ku, Tokyo-To and currently employs 21 full-time employees. The company went IPO on 2021-06-22. The firm is involved in the research and development of therapeutic drugs for cancer and other diseases and related businesses. The firm is involved in the research, development, licensing, and manufacturing method establishment for commercialization in the fields of drug discovery, antibody research support, as well as antibody and reagent sales. The products include PPMX-T001, a therapeutic agent that targets glypican 3 (GPC3) present on the surface of cancer cell membranes; PPMX-T002, a therapeutic agent that targets cadherin 3 (CDH3) present on the surface of cancer cells; PPMX-T003, a therapeutic agent that targets the transferrin receptor (TfR); PPMX-T004 therapeutic agent targeting cadherin 3 (CDH3) and others.

Intrinsic Value
732.02 JPY
Undervaluation 22%
Intrinsic Value
Price

See Also

What is Perseus Proteomics Inc's Cash Taxes Paid?
Cash Taxes Paid
1.9m JPY

Based on the financial report for Mar 31, 2024, Perseus Proteomics Inc's Cash Taxes Paid amounts to 1.9m JPY.

What is Perseus Proteomics Inc's Cash Taxes Paid growth rate?
Cash Taxes Paid CAGR 5Y
15%

Over the last year, the Cash Taxes Paid growth was 0%. The average annual Cash Taxes Paid growth rates for Perseus Proteomics Inc have been 1% over the past three years , 15% over the past five years .

Back to Top